Could less treatment be just as good? study tests Spaced-Out dosing for blood cancer
NCT ID NCT07485647
Summary
This study is testing whether a maintenance therapy for multiple myeloma can be given less often while still working well. It will give the drug combination daratumumab-hyaluronidase every 8 weeks instead of every 4 weeks, along with the pill lenalidomide, to patients who have had a stem cell transplant. The goal is to see if this less frequent schedule is equally effective at keeping the cancer in check while reducing treatment costs and the number of clinic visits for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37203, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.